AN-8025

N/A

Report date: 2025/12/19 10:21:13

Base Information

Drug NameAN-8025
Drug Alias NameAN-8025
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAntigen-presenting cells modulatorsRegulatory T-lymphocytes modulatorsAnti-Programmed death-ligand 1 +[5] 
TargetsProgrammed death-ligand 1Cluster of differentiation 86Lymphocyte activation gene 3 protein
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Adlai Nortye Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHangzhou Adlai Nortye Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A